<p><b>A)</b> HCT116 clones that are relatively cisplatin sensitive (D3, D8) or relatively cisplatin resistant (D6, D7) were untreated (NT) or treated with 15 µM cisplatin for 1–3 days. Cell cycle profiles were determined by flow cytometry. <b>B)</b> The percentage of sub-G1, 2N, S-phase, 4N, or greater than 4N cells was determined at the indicated time points in cisplatin treated cells. Numbers represent the average of 3 separate experiments +/− s.e.m.</p
<p><b>A</b>) LD<sub>50</sub> for cisplatin determined for the SAOS-2 cells. An LD<sub>50</sub> of 10...
<p>Content of DNA adducts (n = 3) in A549 and A549<sup>r</sup>CDDP<sup>2000</sup> cells, treated wit...
<p>Parent (PT) and cisplatin resistant (CisR) cell lines were treated with increasing concentrations...
<p><b>A)</b> HCT116 cells were plated at single cell density and ten individual clones (designated D...
Cisplatin is a platinum-based drug that is used for the treatment of a wide-variety of primary human...
<p>The CP resistant clone D6 was untreated (NT) or treated with 15 µM cisplatin for 6 hrs followed b...
<p><b>A)</b> HCT116 clones were either untreated (NT) or treated with 15 µM cisplatin. At the 24 hr ...
<p>HCT116 clones D6 and D7 were treated with either CP alone for 72 hrs, UCN01 alone for 72 hrs, or ...
<p>Nineteen HNSCC cell lines were continuously treated with 18 different concentrations of cisplatin...
<p>Parent and Cisplatin resistant NSCLC cells were treated with cisplatin for 24 h. Cell cycle distr...
<p>(<b>A</b>) CNE2 and HONE1 stable cell lines were treated with 0 or 2.0 μg/ml cisplatin. The MTT a...
<p>A549, SKMES-1, MOR and H460 PT and CisR cells were seeded in 6-well plates using optimised seedin...
<p><b>A)</b> HCT116 clones D6 and D7 were treated with 15 µM cisplatin (CP) for 24 or 48 hrs, follow...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>NG108-15 cells were treated with 5 µg/ml cisplatin for 12 hours. A final concentration of 10 nmol...
<p><b>A</b>) LD<sub>50</sub> for cisplatin determined for the SAOS-2 cells. An LD<sub>50</sub> of 10...
<p>Content of DNA adducts (n = 3) in A549 and A549<sup>r</sup>CDDP<sup>2000</sup> cells, treated wit...
<p>Parent (PT) and cisplatin resistant (CisR) cell lines were treated with increasing concentrations...
<p><b>A)</b> HCT116 cells were plated at single cell density and ten individual clones (designated D...
Cisplatin is a platinum-based drug that is used for the treatment of a wide-variety of primary human...
<p>The CP resistant clone D6 was untreated (NT) or treated with 15 µM cisplatin for 6 hrs followed b...
<p><b>A)</b> HCT116 clones were either untreated (NT) or treated with 15 µM cisplatin. At the 24 hr ...
<p>HCT116 clones D6 and D7 were treated with either CP alone for 72 hrs, UCN01 alone for 72 hrs, or ...
<p>Nineteen HNSCC cell lines were continuously treated with 18 different concentrations of cisplatin...
<p>Parent and Cisplatin resistant NSCLC cells were treated with cisplatin for 24 h. Cell cycle distr...
<p>(<b>A</b>) CNE2 and HONE1 stable cell lines were treated with 0 or 2.0 μg/ml cisplatin. The MTT a...
<p>A549, SKMES-1, MOR and H460 PT and CisR cells were seeded in 6-well plates using optimised seedin...
<p><b>A)</b> HCT116 clones D6 and D7 were treated with 15 µM cisplatin (CP) for 24 or 48 hrs, follow...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>NG108-15 cells were treated with 5 µg/ml cisplatin for 12 hours. A final concentration of 10 nmol...
<p><b>A</b>) LD<sub>50</sub> for cisplatin determined for the SAOS-2 cells. An LD<sub>50</sub> of 10...
<p>Content of DNA adducts (n = 3) in A549 and A549<sup>r</sup>CDDP<sup>2000</sup> cells, treated wit...
<p>Parent (PT) and cisplatin resistant (CisR) cell lines were treated with increasing concentrations...